Please login to the form below

Not currently logged in

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

NICE (National for Health and Clinical Excellence)New fast-track appraisal a boon for companies

FDA will maintain the pace, vows Woodcock, but warns of skills gap

FDA webTop official unconcerned by dip in approval rate

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

FDA headquarters White OakOne of several anti-CD38 antibodies in pipeline

Trump presses on with reference pricing plan for medicines

Donald TrumpProposed pilot programme to run until 2025

AstraZenca to appeal NICE rejection of Tagrisso

AZ logoPfizer’s Vizimpro wins recommendation

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

LibAcknowledges unmet need

ViiV bags EU okay for new two-drug HIV therapy

ViiV HealthcareRivals Gilead's Biktarvy

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

LibLicensed to treat one of the most commonly diagnosed skin cancers

Brexit‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

Brexit means pharma must review its intellectual property rights across Europe

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...